Statin-associated rhabdomyolysis: Is there a dose-response relationship?

Canadian Journal of Cardiology

Volumn 27, Issue 2, 2011, Pages 146-151

  Holbrook, Anne ^a,b   Wright, Mitchell ^b   Sung, Melani ^c   Ribic, Christine ^a   Baker, Steven ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; ENOXAPARIN; FERROUS GLUCONATE; FLUINDOSTATIN; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; MANNITOL; MEVINOLIN; NIFEDIPINE; PRAVASTATIN; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; TENECTEPLASE; WARFARIN; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; ARTICLE; CANADA; DIALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG UTILIZATION; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; INCIDENCE; LUNG EMBOLISM; MORTALITY; PHYSICAL EXAMINATION; RHABDOMYOLYSIS; UNITED STATES; CASE REPORT; CHEMICALLY INDUCED DISORDER; DYSLIPIDEMIA; FOLLOW UP; MALE; MIDDLE AGED; RETROSPECTIVE STUDY;

DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES; RETROSPECTIVE STUDIES; RHABDOMYOLYSIS;

EID: 79958014049     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2010.12.024     Document Type: Article

References (32)

1. Mitka M. Expanding statin use to help more at-risk patients is causing financial heartburn. JAMA 2003;290:2243-5.
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
3. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45.
4. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-35.
5. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
6. Wagner M, Goetghebeur M, Merikle E, et al. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada. Can J Clin Pharmacol. 2009;16:3331-45.
7. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007;18:401-8.
8. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;30:338: b2376.
9. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292: 2585-90.
10. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150:858-68.
11. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006;119:400-9.
12. Hedenmalm K, Alvan G, Öhagen P, Dahl ML. Muscle toxicity with statins. Pharmacoepidemiol Drug Saf 2010;19:223-31.
13. Alsheikh-Ali A, Maddukuri P. Han H, Karas R. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 2007;50:409-18.
14. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114:2788-97.
15. Health Canada-Medeffect Canada. Canada Vigilance Program. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/vigilance-eng.php. Accessed August 19, 2009.
16. US Food and Drug Administration. The Adverse Event Reporting System (AERS). Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm. Accessed August 20, 2009.
17. Pasternak RC, Smith J, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 2002:33:2337-41.
18. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.
19. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.
20. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol 2003;92:152-60.
21. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-7.
22. Rogers SL, Magliano DJ, Levison DB, et al. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clin Ther 2007;29:242-52.
23. Stone NJ, Blum CB. The Lipid-Lowering Drugs. Management of Lipids in Clinical Practice. 6th ed. Caddo, OK: Professional Communications, 2006: 294-5.
24. Brogan Inc. Available at: http://www.broganinc.com/english/publications/index.html.
25. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006;97:S69-S76.
26. Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 2008;8:333-8.
27. Baker SK, Samjoo IA. A neuromuscular approach to statin-related myotoxicity. Can J Neurol Sci 2008;35:8-21.
28. Link E, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl Med 2008;8:789-99.
29. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006; 34:153-62.
30. Silva M, Matthews ML, Jarvis C, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007;29:253-60.
31. Kalaria D, Wassenaar W. Rhabdomyolysis and cerivastatin: was it a problem of dose? CMAJ 2002;167:737.
32. Piorkowski JD Jr. Bayer's response to "Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis." JAMA 2004;292:2655-7.